Yissum - Research Development Company of the Hebrew University

Targets for precision medicine of glioblastoma and other diseases

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Cluster8
Genetic and Epigenetic Editing for Brain Tumor Control

Project ID : 6-2017-4496

Description of the technology

Keywords

Glioblastoma multiforme, regulatory networks, target genes

Current development stage

TRL3 - hypothesis testing and initial POC demonstrated in-vitro

Application

  • Glioblastoma multiforme (GBM) is a common, very aggressive brain cancer with a dismal prognosis, affecting young and middle-age adults with no effective treatment.
  • Former efforts to diagnose glioblastoma tumors and tailor personal treatments were so far limited to the coding sequences of the cancer genes, but it is lately become clear that the cancer is due to mutation of gene regulation rather than of gene structure
  • The effect of transcriptional enhancers remains unclear due to the lack of an effective way to link enhancers with their controlled genes.

Our Innovation

A novel method to control the activity level of key GBM genes and attack the cancer through its regulatory networks (a new class of genomic targets).

  • Better targets – Provide a new world of regulatory targets
  • Safer treatment - Expression-related epigenetic modifications are tunable and reversible, therefore side effects are better controlled, and the risk of unwanted permanent effects is much lower.
  • Better control - The ability to tune activity level of genes (vs. current gene KO approaches) is revolutionary more effective and provide significantly improved ability for personalized fitting.

Technology

Using a novel mapping technology, a list of critical genomic targets (enhancer sites) for GBM driver genes (unique to our lab and not available for others) were identified in human tumors.

The ability to control glioblastoma proliferation by modifying the regulatory targets via Cas-CRISPR editing was demonstrated.

The activity of the targeted genes was tuned by epigenetic editing of the critical regulatory sites without introducing irreversible genetic modifications

Opportunity

  • Diagnostic and prognosis kits for brain cancer subtypes.
  • Monitoring cancerous tumors during treatment.
  • Biochemical measuring tools for molecular diagnostics.
  • Genetic and epigenetic therapy tools.
  • Indicate existing drugs for additional types of patients.

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Asaf Hellman
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • Oncology / Cancer

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.